Remove Adverse Reactions Remove Blog Remove Labelling
article thumbnail

FDA Unveils Its Own Medical Queries—A Standardized Approach for Grouping MedDRA Preferred Terms that Will Impact NDA/BLA Safety Analyses and Drug Labeling

The FDA Law Blog

For a number of years, FDA has been including groups of related preferred terms in tables in the Adverse Reactions Section of drug labeling (Section 6), generally describing such groupings with the use of footnotes. Such groupings have generally seemed to appear in labeling on an ad hoc basis, without standardization.

article thumbnail

OPDP Says TV Ad is Out of Bounds with Fourth Untitled Letter of 2024

The FDA Law Blog

This letter, dated August 29, 2024, (at the height of the US Open, no less) comes not even a month after OPDP’s last letter from August 1, and a little over a month since another celebrity-related Untitled Letter, both of which we blogged about here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Shanghai ISPE Pharmaceutical Information Company holds 2022 China Pharmaceutical Supply Chain Summit

ISPE

Thanks to the clinical supply chain service companies' years of industry development and operation, there are new developments in global supply chain layout, ultra-low temperature storage and distribution management breakthroughs, and growing packaging and labeling capabilities. Shi Yun, QA Manager of Restone Biomedicine Co.,

article thumbnail

2022 ISPE China Pharmaceutical Supply Chain Summit

ISPE

2022 ISPE China Pharmaceutical Supply Chain Summit Trudy Patterson Tue, 03/28/2023 - 09:24 iSpeak Blog iSpeak 2022 ISPE China Pharmaceutical Supply Chain Summit 28 March 2023 On 17 December 2022, more than 100 people from all over the world gathered online for the 2022 ISPE China Pharmaceutical Supply Chain Summit.

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

Dr. Bernard Bihari is credited with making these discoveries about using naltrexone off-label, at lower doses. IW: What are some of the more common adverse reactions that people have to LDN? These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS.

article thumbnail

The MAHA Assessment’s Implications: Drugs (Part One)

The FDA Law Blog

There are also drugs the Assessment identifies as being used off-label without high-quality evidence or for uses that are approved but without rigorous true placebo-controlled trials (namely vaccines) and/or with known safety concerns.

article thumbnail

Common Hashimoto’s Patterns Seen in the GI-MAP Test

The Thyroid Pharmacist

I started speaking about the connection our stool testing showed between Blasto and Hashimoto’s in 2014, wrote a comprehensive blog about it in 2015, and shared my findings with my Thyroid Mastermind colleagues. 2] So what do these various findings and patterns tell us?